LATEST NEWS & PUBLICATIONS
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing Shifts
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing ShiftsThe Trump administration’s latest policy signals could mark a significant change for the pharmaceutical sector - combining the threat of sweeping tariffs on branded drugs with the...
2026 CMS Proposed Rule: BFSF Clarifications & Compliance Risks for Pharma Manufacturers
2026 CMS Proposed Rule: BFSF Clarifications & Compliance Risks for Pharma Manufacturers On July 16, 2025, CMS released the CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings...
What Pharma Manufacturers Need to Know About the New “One Big Beautiful Bill Act” (OBBBA)
What Pharma Manufacturers Need to Know About the New “One Big Beautiful Bill Act” (OBBBA)Key Takeaways from the Latest Regulatory Reforms Impacting Medicaid, Medicare, and Drug Pricing On July 4, 2025, the "One Big Beautiful Bill Act" (OBBBA) was signed into law,...
OUR DIFFERENCE
Access
- Direct access to your analyst and company leadership
- Available 24/7 to support your needs
Accuracy
- Apply discipline to fully compliant SOPs
- All deliverables subject to strict layers of reviews and audits
Dependability
- Consistent ownership & business partners
- Vested in your long-term success
Transparency
- Clients own all data
- Full access to all scrubbed data, computations and processes
Problems Solved — Opportunities Leveraged.
Find out how we can support your critical analytic, processing and financial functions.